Smoking Cessation Medications: 3 Major Approaches Compared
Evidence synthesis on varenicline, combination NRT, and cytisinicline — with a contextual look at e-cigarettes — for primary care prescribing.
One-Minute Takeaway on Smoking Cessation Medications
One-Minute Takeaway
- First-line smoking cessation medications — varenicline, combination nicotine replacement therapy (NRT), and cytisinicline — each approximately double 6-month abstinence rates compared with placebo across pooled trial evidence.
- Varenicline shows the highest single-agent efficacy in network meta-analyses; the EAGLES trial established no excess risk of serious neuropsychiatric events versus placebo.
- Combination NRT (long-acting patch plus a short-acting form) outperforms single-form NRT and approaches varenicline efficacy in indirect comparisons.
- Cytisinicline offers a shorter, lower-cost alternative; ORCA-2 supports a 12-week regimen, and FDA review is ongoing for US approval.
- Long-term abstinence beyond 12 months, head-to-head cytisinicline-versus-varenicline data, and pregnancy-specific evidence remain important gaps.
Why Smoking Cessation Medications Matter in Family Practice
Tobacco use remains the leading cause of preventable death worldwide, contributing to an estimated 8 million deaths annually. In the United States, roughly 28 million adults still smoke, and family physicians sit at the front line of cessation counseling, prescribing, and follow-up.
Despite robust evidence that smoking cessation medications approximately double 6-month quit rates compared with unassisted attempts, only a minority of smokers receive evidence-based pharmacotherapy. Surveys of primary care prescribing show variable use of varenicline, persistent under-dosing of NRT, and limited awareness of newer agents such as cytisinicline.
The therapeutic landscape has also shifted. The FDA removed the varenicline boxed warning in 2016 following the EAGLES trial, generic varenicline supply has been restored after the 2021 nitrosamine recall, and cytisinicline received a US New Drug Application submission with a regulatory decision pending. Cochrane network meta-analyses have repositioned combination NRT as a near-equivalent alternative to varenicline.
For family physicians, an evidence-based framework for choosing among smoking cessation medications is essential to closing the persistent gap between trial efficacy and population-level cessation rates.
What Evidence Was Reviewed
This synthesis draws on a Cochrane component network meta-analysis covering hundreds of randomized trials of smoking cessation medications, three landmark drug-specific trials (EAGLES, ORCA-2, RAUORA), focused Cochrane reviews of NRT formulations and dosing, and the most recent Cochrane review of electronic cigarettes for cessation.
The table below summarizes the key evidence sources informing the comparative claims in this review.
| Study / Review | Design | n | Population | Primary Comparison | Outcome Window |
|---|---|---|---|---|---|
| Lindson 2023 (Cochrane NMA) | Component NMA | ~157,000 across 332 trials | Adult smokers | All cessation pharmacotherapy + e-cigs vs placebo / each other | ≥6 months |
| EAGLES (Anthenelli 2016) | RCT, 4-arm | 8,144 | Smokers with and without psychiatric disorders | Varenicline vs bupropion vs patch vs placebo | Continuous abstinence wk 9–12; safety to wk 24 |
| ORCA-2 (Rigotti 2023) | RCT, 3-arm | 810 | Adults smoking ≥10 cig/day | Cytisinicline 6 wk vs 12 wk vs placebo | Biochem-confirmed abstinence wk 9–12 and 6 mo |
| Walker 2014 (NEJM) | RCT, open-label | 1,310 | NZ smokers calling Quitline | Cytisine 25-day vs NRT 8-wk | 1 mo and 6 mo abstinence |
| RAUORA (Walker 2021) | RCT, non-inferiority | 679 | Māori / whānau smokers in NZ | Cytisine vs varenicline | 6 mo continuous abstinence |
| Hartmann-Boyce 2018 (Cochrane NRT) | SR / meta-analysis | ~64,000 across 136 trials | Adult smokers | NRT vs placebo / no NRT | ≥6 months |
| Theodoulou 2023 (Cochrane NRT dosing) | SR / meta-analysis | ~50,000 across 75 trials | Adult smokers | High vs standard dose; combination vs single NRT | ≥6 months |
| Hartmann-Boyce 2024 (Cochrane e-cig) | SR / meta-analysis | ~28,000 across 88 trials | Adult smokers | Nicotine e-cigarette vs NRT / behavioral support / placebo | ≥6 months |
| Howes 2020 (Cochrane bupropion) | SR / meta-analysis | ~26,000 across 71 trials | Adult smokers | Bupropion vs placebo / NRT | ≥6 months |
Key Findings on Smoking Cessation Medications
Varenicline Demonstrates Highest Single-Agent Efficacy
Across multiple network meta-analyses, varenicline consistently emerges as the most effective single-agent among smoking cessation medications. Pooled estimates report risk ratios for 6-month continuous abstinence relative to placebo of approximately RR 2.3–2.4 for varenicline, RR 1.8–1.9 for combination NRT, RR 1.5–1.6 for single-form NRT, and RR 1.6–1.7 for bupropion.
The EAGLES trial provided pivotal head-to-head data, randomizing 8,144 smokers across psychiatric and non-psychiatric cohorts to varenicline, bupropion, nicotine patch, or placebo over 12 weeks. Continuous abstinence rates from weeks 9–12 reached approximately 33% with varenicline versus 23% with patch, 22% with bupropion, and 12% with placebo in the non-psychiatric cohort.
Critically, EAGLES also resolved years of safety controversy by demonstrating no significant excess of serious neuropsychiatric adverse events with varenicline or bupropion versus placebo or patch. The FDA removed the varenicline boxed warning in 2016 in light of these findings, though clinicians should still review mood and behavior at follow-up.
Combination NRT Outperforms Monotherapy
Pairing a long-acting nicotine patch with a short-acting form — gum, lozenge, inhaler, or nasal spray — consistently yields superior abstinence outcomes compared with single-form NRT alone. Cochrane evidence indicates combination NRT achieves quit rates roughly 25–35% higher than monotherapy and approaches the efficacy of varenicline in indirect comparisons.
The mechanism behind this advantage relates to dual coverage. The patch addresses tonic baseline craving across the day, while the short-acting form addresses acute craving spikes triggered by smoking-associated cues. Higher-dose patch protocols for heavier smokers and pre-quit NRT initiation 2–4 weeks before the target quit date represent additional efficacy levers supported by recent trial evidence.
Clinical pearl on smoking cessation medications: When patients prefer NRT or have varenicline contraindications, combination NRT (21 mg patch plus 2 mg or 4 mg lozenges as needed) is the next strongest evidence-based option — not single-form NRT.
Cytisinicline Shows Comparable Efficacy at Lower Cost
Cytisinicline (also marketed as cytisine in some jurisdictions) is a partial nicotinic acetylcholine receptor agonist with a mechanism similar to varenicline. The ORCA-2 trial randomized 810 adult smokers to cytisinicline 3 mg three times daily for 6 weeks, 12 weeks, or matching placebo and demonstrated biochemically-confirmed continuous abstinence at weeks 9–12 of approximately 32% in the 12-week arm versus 7% with placebo.
A 2014 New Zealand trial by Walker and colleagues compared a cytisine 25-day course with 8-week NRT in 1,310 motivated smokers and found cytisine non-inferior to NRT for 1-month continuous abstinence at substantially lower per-course cost. The RAUORA trial compared cytisine and varenicline in Māori smokers and found broadly similar efficacy, though confidence intervals included clinically meaningful differences.
Among emerging smoking cessation medications, cytisinicline is unique in offering a treatment course as short as 6–12 weeks at a fraction of varenicline’s cost. Direct head-to-head trials of cytisinicline versus varenicline in non-indigenous populations remain limited.
E-Cigarettes Occupy a Contested Evidence Position
Cochrane evidence indicates that nicotine-containing electronic cigarettes are associated with higher 6-month abstinence rates than NRT in trials randomizing motivated quitters. The most recent Cochrane review included 88 trials and rated certainty of evidence for the e-cigarette versus NRT comparison as high.
However, several considerations limit clinical adoption. E-cigarettes are not FDA-approved as cessation pharmacotherapy in the United States, dual use with combustible cigarettes is common and undermines health gains, and long-term safety data beyond 1–2 years remain sparse. Major guideline bodies have not endorsed e-cigarettes as first-line smoking cessation medications.
EAGLES enrolled 8,144 motivated quitters across 16 countries, stratified into psychiatric and non-psychiatric cohorts of approximately 4,000 each. Randomization was 1:1:1:1 to varenicline 1 mg twice daily, bupropion SR 150 mg twice daily, nicotine patch 21 mg/day with taper, or matching placebo, all alongside brief behavioral counseling.
Two questions were answered:
- Efficacy: Varenicline produced higher continuous abstinence rates than each comparator in both cohorts.
- Safety: The composite of moderate-to-severe neuropsychiatric adverse events was not significantly higher with active drugs than with placebo or patch in either cohort, even among smokers with stable psychiatric diagnoses.
EAGLES was not designed to address acute psychiatric instability, active substance use disorders, or pregnancy.
ORCA-2 was a phase 3, three-arm, double-blind RCT enrolling 810 adults smoking ≥10 cigarettes per day across 17 US sites. Participants received cytisinicline 3 mg three times daily for 6 weeks (with placebo for weeks 7–12), cytisinicline 3 mg three times daily for 12 weeks, or placebo throughout.
The primary outcome — biochemically-verified continuous smoking abstinence during weeks 9 through 12 — favored both cytisinicline arms over placebo, with the 12-week course showing larger effect estimates than the 6-week course. Discontinuation due to adverse events was low and comparable across arms.
Long-term outcomes at 24 weeks favored cytisinicline but with narrower margins, illustrating the well-known erosion of cessation effects after pharmacotherapy ends.
A common evidence-aligned starting regimen for adult smokers consuming ≥10 cigarettes per day:
- Patch (long-acting): 21 mg/day for 6 weeks, then 14 mg/day for 2 weeks, then 7 mg/day for 2 weeks.
- Short-acting (as needed): 2 mg lozenge or gum every 1–2 hours for cravings (4 mg if first cigarette within 30 minutes of waking), capped per product labeling.
Pre-quit NRT (starting the patch 2 weeks before the target quit date) has shown improved abstinence in several trials. Higher-dose patch protocols (e.g., 42 mg/day in heavy smokers) have evidence in select populations but are off-label.
Common reasons combination NRT under-performs in primary care include subtherapeutic short-acting dosing, insufficient duration, and skin reactions to the patch leading to early discontinuation.
Bupropion SR remains an FDA-approved cessation agent with efficacy superior to placebo and broadly comparable to single-form NRT. It is generally less effective than varenicline as monotherapy in network meta-analyses but offers practical advantages in selected patients:
- Comorbid depression, where bupropion may also address mood symptoms.
- Patients motivated by potential weight-related effects, given bupropion’s weight-neutral to modestly weight-suppressing profile.
- Patients with prior intolerance to nicotine-based products or varenicline.
Seizure risk remains the principal safety concern, and bupropion is contraindicated with seizure disorders, eating disorders, and concurrent MAOIs.
The 2024 Cochrane review reports nicotine e-cigarettes outperform NRT for 6-month abstinence in motivated quitters, with high certainty for that comparison. However, several practical caveats apply when generalizing this signal to primary care:
- Trial participants were typically counseled and supplied with regulated devices and liquids — different from over-the-counter vape products in the US retail environment.
- Dual use (continued combustible cigarette use alongside vaping) was common and reduces realized health benefits.
- FDA has not authorized any e-cigarette as a smoking cessation device, though some products carry tobacco-product authorizations for adult smoker switching.
- Long-term cardiovascular and pulmonary outcomes beyond 24 months remain understudied, and youth uptake is a population-level concern.
Quality & Consistency of Evidence on Smoking Cessation Medications
The evidence base supporting smoking cessation medications is among the most mature in chronic disease prevention, but consistency varies meaningfully across drug classes and outcomes.
What the Evidence on Smoking Cessation Medications Does Not Show
Several specific gaps remain. Naming them clearly helps clinicians counsel patients honestly and prioritize research participation when feasible.
Specific Evidence Gaps
- Long-term abstinence beyond 12 months: Most pivotal trials report 6-month outcomes; data on 2- to 5-year sustained abstinence with any pharmacotherapy are limited.
- Cytisinicline versus varenicline head-to-head: Direct comparisons exist primarily in the New Zealand Māori population (RAUORA); generalizable comparative-effectiveness data in broader populations are pending.
- Optimal cytisinicline duration: ORCA-2 suggests 12 weeks is more effective than 6 weeks, but maintenance and re-treatment strategies are unstudied.
- Real-world adherence: Trial adherence (≈70–80%) substantially exceeds primary care adherence (≈30–50%); strategies to bridge this gap are not well characterized.
- E-cigarette long-term safety: Cardiovascular, pulmonary, and oncologic outcomes beyond 24 months are sparse.
- Pregnancy: Evidence for varenicline and cytisinicline in pregnancy is essentially absent. NRT remains the default with mixed efficacy.
- Heavy smokers (>30 cigarettes/day): Most trials enrolled moderate smokers; high-burden populations are under-represented.
- Severe mental illness, polysubstance use, active malignancy: Limited dedicated trial evidence; observational data suggest benefit but with greater effect heterogeneity.
- Adolescents and young adults: Pharmacotherapy evidence in those under 18 is very limited; behavioral interventions remain first-line.
Practical Implications
Based on the current evidence on smoking cessation medications, the following considerations may help structure prescribing decisions in family practice. These are framed as evidence-supported considerations rather than directive recommendations.
Evidence Supports Varenicline as First-Line Single Agent
Cochrane network meta-analyses show the highest single-agent abstinence effect, and EAGLES established the absence of significant excess neuropsychiatric risk. Standard 12-week course; longer courses are reasonable in patients with partial response.
Combination NRT Approaches Varenicline Efficacy
Long-acting patch plus a short-acting form is supported when patients prefer nicotine-based therapy, have varenicline contraindications, or in pregnancy where NRT is the default option. Subtherapeutic short-acting dosing is the most common implementation pitfall.
Cytisinicline Offers Shorter Course Alternative
ORCA-2 supports a 12-week regimen as an effective option pending broader US availability and longer-term data. Cost-sensitive patients and those who prefer a shorter pharmacologic course may benefit most.
Behavioral Counseling Amplifies All Pharmacotherapy
Brief counseling, quitlines, and digital programs produce additive effects across all smoking cessation medications. Even short physician advice (3–5 minutes) shifts cessation rates and is captured in most quality metrics.
Implementation Considerations
Effect sizes from trial populations may overstate primary care results due to higher trial-level motivation and adherence. Setting realistic expectations with patients — typical 6-month quit rates of 25–35% with the most effective regimens — supports persistence and re-attempt after relapse, which is often part of the eventual quit trajectory.
Evidence Grade & Bottom Line
Overall Evidence Grade: STRONG — for varenicline, NRT (any form), and combination NRT vs placebo, supported by multiple high-quality RCTs and current Cochrane network meta-analyses. MODERATE for cytisinicline efficacy vs placebo. MIXED for e-cigarettes when weighing efficacy against regulatory status and long-term safety uncertainty.
Bottom Line
- Varenicline, combination NRT, and cytisinicline are the three smoking cessation medications with the strongest current evidence, each approximately doubling 6-month abstinence relative to placebo.
- EAGLES resolved earlier neuropsychiatric concerns for varenicline, and the FDA boxed warning has been removed; periodic mood and behavior review remains good practice.
- Combination NRT outperforms single-form NRT and is the strongest non-varenicline first-line option, particularly relevant in pregnancy and in patients preferring nicotine-based therapy.
- Cytisinicline offers a shorter and lower-cost course; head-to-head data versus varenicline and longer-term outcomes will refine its role over time.
- E-cigarettes show emerging efficacy in trials but lack FDA cessation indication, and durable safety remains uncertain — they should not yet displace established smoking cessation medications in primary care.
Article Information & References
For Educational Purposes Only. This is an original evidence synthesis informed by the studies listed below. It does not replace clinical judgement. Drug dosages should be verified against current prescribing information.
References
- Lindson N, Theodoulou A, Ordóñez-Mena JM, et al. Pharmacological and electronic cigarette interventions for smoking cessation in adults: component network meta-analyses. Cochrane Database Syst Rev. 2023;9:CD015226. DOI: 10.1002/14651858.CD015226.pub2
- Anthenelli RM, Benowitz NL, West R, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet. 2016;387(10037):2507–2520. DOI: 10.1016/S0140-6736(16)30272-0
- Rigotti NA, Benowitz NL, Prochaska JJ, et al. Cytisinicline for smoking cessation: a randomized clinical trial. JAMA. 2023;330(2):152–160. DOI: 10.1001/jama.2023.10042
- Walker N, Howe C, Glover M, et al. Cytisine versus nicotine for smoking cessation. N Engl J Med. 2014;371(25):2353–2362. DOI: 10.1056/NEJMoa1407764
- Walker N, Smith B, Barnes J, et al. Cytisine versus varenicline for smoking cessation in New Zealand indigenous Māori: a randomized controlled trial. Addiction. 2021;116(10):2847–2858. DOI: 10.1111/add.15489
- Hartmann-Boyce J, Chepkin SC, Ye W, Bullen C, Lancaster T. Nicotine replacement therapy versus control for smoking cessation. Cochrane Database Syst Rev. 2018;5:CD000146. DOI: 10.1002/14651858.CD000146.pub5
- Theodoulou A, Chepkin SC, Ye W, et al. Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2023;6:CD013308. DOI: 10.1002/14651858.CD013308.pub2
- Lindson N, Klemperer E, Hong B, Ordóñez-Mena JM, Aveyard P. Smoking reduction interventions for smoking cessation. Cochrane Database Syst Rev. 2019;9:CD013183. DOI: 10.1002/14651858.CD013183.pub2
- Hartmann-Boyce J, Lindson N, Butler AR, et al. Electronic cigarettes for smoking cessation. Cochrane Database Syst Rev. 2024;1:CD010216. DOI: 10.1002/14651858.CD010216.pub8
- Howes S, Hartmann-Boyce J, Livingstone-Banks J, Hong B, Lindson N. Antidepressants for smoking cessation. Cochrane Database Syst Rev. 2020;4:CD000031. DOI: 10.1002/14651858.CD000031.pub5
- Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev. 2013;5:CD009329. DOI: 10.1002/14651858.CD009329.pub2
- Claire R, Chamberlain C, Davey MA, et al. Pharmacological interventions for promoting smoking cessation during pregnancy. Cochrane Database Syst Rev. 2020;3:CD010078. DOI: 10.1002/14651858.CD010078.pub3
- US Preventive Services Task Force. Interventions for tobacco smoking cessation in adults, including pregnant persons: US Preventive Services Task Force recommendation statement. JAMA. 2021;325(3):265–279. DOI: 10.1001/jama.2020.25019
- Livingstone-Banks J, Fanshawe TR, Thomas KH, et al. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2023;5:CD006103. DOI: 10.1002/14651858.CD006103.pub8
- Hartmann-Boyce J, Hong B, Livingstone-Banks J, Wheat H, Fanshawe TR. Additional behavioural support as an adjunct to pharmacotherapy for smoking cessation. Cochrane Database Syst Rev. 2019;6:CD009670. DOI: 10.1002/14651858.CD009670.pub4